Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.13/807893

OpenURL Link
Title
Intranasal sufentanil for cancer-associated breakthrough pain
Author/Creator
Good, P.;  Jackson, K.;  Brumley, D.;  Ashby, M.
Institution
The University of Newcastle. Faculty of Health, School of Medicine and Public Health
Description
The objective of this study was to demonstrate the efficacy, safety and patient acceptability of the use of intranasal sufentanil for cancer-associated breakthrough pain. This was a prospective, open label, observational study of patients in three inpatient palliative care units in Australia. Patients on opioids with cancer-associated breakthrough pain and clinical evidence of opioid responsiveness to their breakthrough pain were given intranasal (IN) Sufentanil via a GO Medical™ patient controlled IN analgesia device. The main outcome measures were pain scores, need to revert to previous breakthrough opioid after 30 min, number of patients who chose to continue using IN sufentanil, and adverse effects. There were 64 episodes of use of IN sufentanil for breakthrough pain in 30 patients. There was a significant reduction in pain scores at 15 (P < 0.0001) and 30 min (P < 0.0001). In only 4/64 (6%) episodes of breakthrough pain did the participants choose to revert to their prestudy breakthrough medication. Twenty-three patients (77%) rated IN sufentanil as better than their prestudy breakthrough medication. The incidence of adverse effects was low and most were mild. Our study showed that IN sufentanil can provide relatively rapid onset, intense but relatively short lasting analgesia and in the palliative care setting it is an effective, practical, and safe option for breakthrough pain.
Relation
Palliative Medicine Vol. 23, Issue 1, p. 54-58
Publisher Link
http://dx.doi.org/10.1177/0269216308100249
Date
2009
Publisher
Sage
Keyword(s)
breakthrough pain;  cancer;  opioid;  sufentanil
Resource Type
journal article
Identifier
http://hdl.handle.net/1959.13/807893
Identifier
ISSN:0269-2163
Reviewed
Reviewed
77 Visitors 93 Hits 0 Downloads
Save/E-mail Citation
Citation Format
E-mail Address
Subject
"Palliative Medicine"
 
OR